Compugen (NASDAQ:CGEN) delivered a transformative fiscal 2025, reporting a sharp pivot to profitability and a significantly bolstered balance sheet.
The Tel Aviv-based clinical-stage company recorded total annual revenue of $72.8 million, a dramatic increase from $27.9 million in 2024.
The growth was primarily driven by a $65 million upfront payment from AstraZeneca (NASDAQ:AZN) following the strategic monetization of a portion of Compugen’s future royalties on rilvegostomig.
The influx of non-dilutive capital helped Compugen achieve a net profit of $35.3 million for the full year, compared to a net loss of $14.2 million in 2024.
For the fourth quarter alone, net profit reached $56.8 million on revenue of $67.3 million.
As of December 31, 2025, the company held $145.6 million in cash and investments, which management estimates will fund operations into 2029.
The year also marked a significant milestone in leadership, with Dr. Eran Ophir—formerly Chief Scientific Officer—assuming the role of President and CEO.
Under his direction, Compugen has intensified its focus on its high-value "DNAM-1 axis" programs.
The company's lead clinical program, the MAIA-ovarian platform trial, is currently evaluating COM701 as a maintenance therapy for platinum-sensitive ovarian cancer.
Enrollment is ongoing across sites in the U.S., Israel, and France, with a highly anticipated interim analysis expected in the first quarter of 2027.
Simultaneously, the Gilead-partnered GS-0321 program remains in Phase 1 development for advanced solid tumors, with Gilead set to assume sole responsibility for late-stage commercialization following the initial dose-escalation phase.